-
Multicriteria Health Technology Assessments for High-Cost Oncology Drugs in Peru: A Cross-Sectional Study of RENETSA Records 2023-2024
Sep 9, 2025, 16:22 PM -
Importance of Decisional Context in the Health Technology Assessment (HTA) of Ultra-Orphan Drugs
Sep 9, 2025, 16:22 PM -
Characterizing Exploratory Endpoints in Early Oncology Trials: Insights From Trial Registry Audit
Sep 9, 2025, 16:22 PM -
Treatment Patterns and Healthcare Resource Utilization in Patients With Chronic Inflammatory Demyelinating Polyneuropathy in England: A Retrospective, Observational Cohort Study
Sep 9, 2025, 16:22 PM -
Cost of Illness Studies Published Between 2010 and 2023 in Türkiye
Sep 9, 2025, 16:22 PM -
Economic Consequences of Disease-Related Malnutrition in Poland and the Potential Cost Savings From Nutritional Interventions: A Two-Step Modeling Study
Sep 9, 2025, 16:22 PM -
The Economic Burden of Diabetes-Related Blindness and Vision Impairment in Saudi Arabia
Sep 9, 2025, 16:22 PM -
What Is the Impact of Patient Voice on NICE Recommendations for Drugs Assessed in 2024?
Sep 9, 2025, 16:22 PM -
A Health Economic Evaluation of Daylight: A Digital Treatment for Anxiety in NHS South Yorkshire
Sep 9, 2025, 16:22 PM -
Real-World Analysis of Treatment Patterns and Disease Exacerbations Among Patients Initiating Therapy for Myasthenia Gravis
Sep 9, 2025, 16:22 PM -
Guideline-Driven Off-Label Oncology Use: The Role of Clinical Evidence and Reimbursement Dynamics in the EU4+UK, Switzerland, and Canada
Sep 9, 2025, 16:22 PM -
Patients’ Advocacy Groups in Italy: An Updated Perspective on Activities and Future Directions
Sep 9, 2025, 16:22 PM -
Impact of Real-World Effectiveness vs. Previous Assumptions on Estimates of Economic and Clinical Benefit of 20-Valent Pneumococcal Conjugate Vaccine in Adults Across Countries
Sep 9, 2025, 16:22 PM -
Evaluating the Effectiveness of Interventions to Reduce Gender Disparities in Healthcare: An Overview of Literature Reviews
Sep 9, 2025, 16:22 PM -
A Systematic Review of Using Social Return on Investments Within Healthcare Service Evaluations: Methodological Opportunity and Challenges
Sep 9, 2025, 16:22 PM -
The Statistical Abyss: Real-World Evidence for Health Technology Assessment
Sep 9, 2025, 16:22 PM -
The Role of Unpaid Work in Measuring the Social Costs of Disease
Sep 9, 2025, 16:22 PM -
Associations of Product-Specific and Clinical Evidence Quality Characteristics With Health Technology Assessment Outcomes: A Quantitative Assessment of Appraisals for Drugs for Rare Diseases in England and Germany
Sep 9, 2025, 16:22 PM -
Pricing Analysis of Value-Added Medicines (VAMs) in Europe: A Call for Recognition of Patient-Centric Innovation
Sep 9, 2025, 16:22 PM -
Economic Evaluation of Surfactant Therapy for Neonatal Respiratory Distress Syndrome: 5-Year Real-World Evidence on Poractant Alfa vs. Beractant From the IMSS Perspective in Mexico
Sep 9, 2025, 16:22 PM
